Since p53 has been reported as a non-histone protein that can be acetylated by HAT,457 a drive in research to study other non-histone targets of HDACs and HATs, such as c-MYC, NF-κB, STAT3, α-tubulin has occurred.458 The non-histone proteins acetylation and deacetylation play roles in all sorts of human diseases, including RA, cancer, and Parkinson’s disease (PD).459–461 Therefore, targeting non-histone proteins might be a promising therapeutic strategy for the treatment of RA. This evidence concerns the gene TP53 and rheumatoid arthritis.